XOMA Royalty Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

XOMA Royalty şirketinin toplam hissedar öz sermayesi $84.8M ve toplam borcu $117.9M olup, bu da borç-öz sermaye oranını 139% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $223.3M ve $138.5M dir.

Anahtar bilgiler

139.0%

Borç/özkaynak oranı

US$117.92m

Borç

Faiz karşılama oranı	n/a
Nakit	US$142.84m
Eşitlik	US$84.81m
Toplam yükümlülükler	US$138.53m
Toplam varlıklar	US$223.34m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: X0M1 'nin kısa vadeli varlıkları ( $159.0M ) kısa vadeli yükümlülüklerini ( $21.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: X0M1 şirketinin kısa vadeli varlıkları ( $159.0M ) uzun vadeli yükümlülüklerini ( $117.4M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: X0M1 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: X0M1 şirketinin borç/öz sermaye oranı son 5 yılda 126.7% seviyesinden 139% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: X0M1 şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: X0M1 serbest nakit akışı her yıl % 16.7 oranında tarihsel oranda büyümeye devam ederse 3 yıldan fazla bir süre için yeterli nakit akışına sahip olur

XOMA Royalty Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Third quarter 2024 earnings released: US$1.59 loss per share (vs US$0.60 loss in 3Q 2023)

Insufficient new directors

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: EPS: US$1.37 (vs US$0.59 loss in 2Q 2023)

First quarter 2024 earnings released: US$0.86 loss per share (vs US$0.98 loss in 1Q 2023)

XOMA Corporation (NasdaqGM:XOMA) completed the acquisition of Kinnate Biopharma Inc. (NasdaqGS:KNTE).

XOMA Corporation, Annual General Meeting, May 15, 2024

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

Xoma Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

XOMA Corporation (NasdaqGM:XOMA) announces an Equity Buyback for $50 million worth of its shares.

New minor risk - Profitability

Third quarter 2023 earnings released: US$0.60 loss per share (vs US$0.48 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.59 loss per share (vs US$0.53 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.98 loss per share (vs US$0.32 loss in 1Q 2022)

Full year 2022 earnings released: US$1.50 loss per share (vs US$0.69 profit in FY 2021)

Investor sentiment improved over the past week

XOMA Corporation Appoints Owen Hughes as Interim Chief Executive Officer

Investor sentiment improved over the past week

Third quarter 2022 earnings released: US$0.48 loss per share (vs US$0.51 loss in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: US$0.53 loss per share (vs US$0.31 loss in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

XOMA Corporation(NasdaqGM:XOMA) dropped from Russell 2000 Dynamic Index

First quarter 2022 earnings released: US$0.32 loss per share (vs US$0.70 loss in 1Q 2021)

Investor sentiment deteriorated over the past week

XOMA Corporation, Annual General Meeting, May 18, 2022

Now 22% undervalued

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: US$0.51 loss per share (vs US$0.098 loss in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: US$0.31 loss per share (vs US$0.33 loss in 2Q 2020)

CEO & Director recently sold €254k worth of stock

First quarter 2021 earnings released: US$0.70 loss per share (vs US$0.49 loss in 1Q 2020)

Full year 2020 earnings released: EPS US$0.82 (vs US$0.23 loss in FY 2019)

Revenue beats expectations

New 90-day high: €29.32

XOMA Earns First Milestone Payment from 2018 Royalty Purchase Agreement

Revenue misses expectations

Third quarter 2020 earnings released: US$0.098 loss per share

New 90-day high: €20.84

XOMA Corporation Earns $25 Million Milestone Payment

XOMA Corporation announced that it has received $1.4 million in funding from Rezolute, Inc.

New 90-day high: €17.92

XOMA Corporation to Report Q2, 2020 Results on Aug 06, 2020

Earnings released

New 90-day low - €14.03

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin